ClinicalTrials.gg
CompletedNCT01357837Updated Jul 15, 2021

Assessment of GRT6005 in Painful Osteoarthritis of the Knee

A Phase 2 interventional study of Matching Placebo and GRT6005 in Osteoarthritis of the Knee, sponsored by Tris Pharma, Inc.. Completed at 26 sites in 3 countries. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-07-15.

Sponsored by Tris Pharma, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
207
Allocation
Randomized
Ages
40 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 77 studies in Osteoarthritis, Knee with a site in Poland — 12 open to participants now, 13 under way, 2 of them phase 3. Osteoarthritis, Knee · Poland.

Enrollment
27th of 71
207 · median 120
Started
2011
the only one that year
Phase 2
13 of 77
none open now
Registered
5th of 77
by date

Among the 77 studies in Osteoarthritis, Knee with a site in Poland, this one is the 27th largest by enrollment of the 71 interventional ones that give a count, is the only one that started in 2011, is one of 13 in phase 2, and was the 5th registered.

Osteoarthritis, Knee

3,295 studies on the registry are indexed under Osteoarthritis, Knee; 624 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

12 of the 77 studies in Osteoarthritis, Knee with a site in Poland are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 383 Osteoarthritis, Knee studies recruiting now, 177 (46%) set no upper age limit and 113 (30%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 40 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 77 studies in Osteoarthritis, Knee with a site in Poland, or all of them as a file.
02

Study summary

The purpose of the trial is to determine whether GRT6005 is effective in patients with pain due to osteoarthritis of the knee.

Read the detailed description

The purpose of this study is to evaluate the safety, tolerability and efficacy of 3 doses of GRT6005 taken once daily for 4 weeks in outpatients with moderate-to-severe painful osteoarthritis of the knee.

03

Conditions studied

  • Osteoarthritis of the Knee

Keywords

  • Osteoarthritis, knee
  • Analgesia
  • Pain
  • Painful
04

Who can participate

Ages eligible
40 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • painful Osteoarthritis of the knee based on American College of Rheumatology Criteria
  • signed
  • on stable analgesic medications for painful osteoarthritis with regular analgesic intake for at least 3 months
  • pain intensity score of 4 or greater on the 11-point numeric rating scale (where 0 indicates "no pain" and 10 indicates "pain as bad as you can imagine").

Exclusion criteria

Exclusion Criteria:

  • Substance Abuse
  • Significant cardiac disease
  • Presence of risk factors for Torsades de Pointes and chronic severe cardiac disease
  • History of seizure disorder
  • Chronic gastrointestinal disease
  • Conditions that contribute and confound to the assessment of pain
  • Surgery or painful procedure during or within 3 months of enrollment
  • Cancer
  • Subjects with impaired renal function
  • Subjects with impaired hepatic function
  • Female subjects who are breastfeeding
  • History of chronic or C or infection, or presence of acute hepatitis A, B, or C within the past 3 months.
  • history of or allergy to paracetamol, opioids or the .
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
207 participants (actual)

Study arms

  • Placebo comparator
    Matching Placebo

    Once daily oral administration of matching placebo for 4 weeks.

    Drug: Matching Placebo

  • Experimental
    75 µg GRT6005

    Once daily oral administration of GRT6005 for 4 weeks.

    Drug: GRT6005

  • Experimental
    200 µg GRT6005

    Once daily oral administration of GRT6005 for 4 weeks.

    Drug: GRT6005

  • Experimental
    400 µg GRT6005

    Once daily oral administration of GRT6005 for 4 weeks.

    Drug: GRT6005

Interventions

  • DrugMatching Placebo

    2 capsules of matching placebo once a day, in the morning, for a total of 28 days

  • 2 capsules containing a total of 75 µg GRT6005 once a day, in the morning, for a total of 28 days

  • 2 capsules containing a total of 200 µg GRT6005 once a day, in the morning, for a total of 28 days

  • 2 capsules containing a total of 400 µg GRT6005 once a day, in the morning, for a total of 28 days

06

What researchers measure

Primary outcomes

  1. Change from baseline in the pain intensity scores during the last week of the 4-week treatment period

    Time frame: 4 weeks

Secondary outcomes

  1. Change from baseline in the Western Ontario McMaster Questionnaire (WOMAC) Global Score Assessing Pain, Disability and Joint Stiffness of the Knee Over the 4 week treatment period

    Time frame: 4 weeks

  2. Change from baseline in quality of health as measured by Short Form-12 Health Survey

    Time frame: 4 weeks

  3. Response measured in percentage change of pain intensity since baseline

    Time frame: 4 weeks

  4. Leeds Sleep Evaluation Questionnaire to quantify subjective impressions of sleep and waking

    Time frame: 4 weeks

  5. Patient's Global Impression of Change (PGIC)

    Time frame: 4 weeks

  6. Clinician's Global Impression of Change (CGIC)

    Time frame: 4 weeks

  7. Weekly current pain intensity changes from baseline

    Time frame: 4 weeks

  8. Rescue medication use

    Time frame: 4 weeks

  9. Quality of Life EuroQoL-5 Dimension score, change from baseline

    Time frame: 4 weeks

  10. Clinical Opioid Withdrawal Scale

    Time frame: 4 weeks

  11. Plasma concentration

    Time frame: 4 weeks

  12. Discontinuation from study due to treatment related adverse events

    Time frame: 4 weeks

  13. Time to withdrawal from study

    Time frame: 4 weeks

07

Study locations

26 sites
  • Site 3604
    Linz, 4021, Austria
  • Site 3605
    Senftenberg, 3541, Austria
  • Site 3603
    Wien, 1090, Austria
  • Site 3602
    Wien, 1100, Austria
  • Site 3601
    Wien, 1130, Austria
  • Site 3203
    Bialystok, 15-337, Poland
  • Site 3202
    Elblag, 82-300, Poland
  • Site 3208
    Gdynia, 81-834, Poland
  • Site 3206
    Krakow, 30-349, Poland
  • Site 3207
    Lublin, 20-605, Poland
  • Site 3210
    Szczecin, 71-252, Poland
  • Site 3201
    Torun, 87-100, Poland
  • Site 3204
    Warsawa, Poland
  • Site 3211
    Warszawa, 02-730, Poland
  • Site 3213
    Wloszczowa, 29-100, Poland
  • Site 3205
    Wroclaw, 50-088, Poland
  • Site 3305
    Barcelona, 08028, Spain
  • Site 3302
    Barcelona, 08034, Spain
  • Site 3303
    Coruna, 15006, Spain
  • Site 3312
    Málaga, 29009, Spain
  • Site 3308
    Mérida, 06800, Spain
  • Site 3310
    Oviedo, 33009, Spain
  • Site 3311
    Petrel, 03610, Spain
  • Site 3304
    Santiago de Compostela, 15705, Spain
  • Site 3306
    Sevilla, 41009, Spain
  • Site 3313
    Torrelavega, 39300, Spain
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2011, a primary completion of Dec 2011 and a completion of Dec 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 19, 2011
First posted
May 23, 2011
Start
May 2011
Primary completionActual
Dec 2011
CompletionActual
Dec 2011
Last update
Jul 15, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01357837
Lead sponsor
Tris Pharma, Inc.
Collaborators
Forest Laboratories
Responsible party
Sponsor
First posted
May 23, 2011
Start date
May 2011
Primary completion
Dec 2011
Completion
Dec 2011
Last update
Jul 15, 2021

Study contacts

Jacek Olas, MD
principal investigator · Specjalistyczne Centrum Medyczne NZOZ NOWOMED,

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cebranopadol

Start the discussion